secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001099800-24-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q4 sales $1.53B (+14% YoY); 2024 guidance reiterated with higher TMTT outlook
--------------------------------------------------------------------------------

- Q4 2023 sales $1.53B (+14% reported, +13% constant currency); TAVR $979M (+13%).
- Q4 GAAP EPS $0.61, adjusted EPS $0.64; full-year 2023 EPS $2.30 (GAAP), $2.51 adjusted.
- TMTT sales $56M in Q4, $198M full year (+65% constant currency); EVOQUE received FDA approval for tricuspid regurgitation.
- 2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80; Q1 sales $1.53-1.61B.
- Repurchased $444M in Q4, $867M in 2023; $1B remaining authorization; cash $1.6B, debt $600M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/ew-20240206.htm
  HTML page:      https://secwatch.observer/filing/0001099800-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer